2.5(top 20%)
impact factor
5.2K(top 5%)
papers
174.8K(top 2%)
citations
139(top 5%)
h-index
2.6(top 20%)
impact factor
6.6K
all documents
181.2K
doc citations
195(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerationsProstate1983974
2Family history and the risk of prostate cancerProstate1990609
3Molecular characterization of human prostate carcinoma cell linesProstate2003555
4The zonal anatomy of the prostateProstate1981521
5Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate CancerProstate2004475
6Etiology and disease process of benign prostatic hyperplasiaProstate1989453
7Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylationProstate1993407
8Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse modelProstate2003402
9The TNM classification of prostate cancerProstate1992383
10Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancersProstate1986367
11PC3 is a cell line characteristic of prostatic small cell carcinomaProstate2011365
12Distribution of metastatic sites in patients with prostate cancer: A population‐based analysisProstate2014352
13Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigenProstate1996337
14Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacementProstate1987330
15LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasisProstate2000328
16Antagonistic effect of androgen on prostatic cell deathProstate1984327
17Radiation therapy for carcinoma of the prostateProstate1981324
18The prostate: An increasing medical problemProstate1990321
19Prostate antigen: A new potential marker for prostatic cancerProstate1981319
20Increased Nox1 and hydrogen peroxide in prostate cancerProstate2005309
21New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensProstate1983305
22Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patientsProstate1996294
23Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivoProstate2001292
24Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapyProstate2011287
25High-grade prostate cancer is associated with low serum testosterone levelsProstate2001280
26Androgen deprivation therapy for prostate cancer: Current status and future prospectsProstate2004279
27p53 oncogene mutations in three human prostate cancer cell linesProstate1993276
28Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancerProstate2011273
29Structural heterogeneity and protein composition of exosome‐like vesicles (prostasomes) in human semenProstate2009271
30Regulation of prostatic growth and function by peptide growth factorsProstate1996269
31Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancerProstate1998269
32Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled TrialProstate1999262
33Androgen-repressed messages in the rat ventral prostateProstate1986254
34Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castrationProstate1989246
35Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and stagingProstate1985243
36Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignanciesProstate2010241
37TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patientsProstate2011239
38Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancerProstate2010233
39The proliferative function of basal cells in the normal and hyperplastic human prostateProstate1994231
40CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12Prostate2006229
41Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathwayProstate2000228
42Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysisProstate2009227
43Proteomic analysis of human prostasomesProstate2003226
44Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasionProstate2006225
45High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancerProstate2011224
46Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: Apoptotic bodies, microvesicles, and exosomesProstate2014223
47Mechanisms of constitutive NF-κB activation in human prostate cancer cellsProstate2002221
48Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancerProstate2002220
49LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an­­d Serve as Models for Evaluating Cancer TherapeuticsProstate2017219
50Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low‐risk, localized prostate cancerProstate2013217